Drug Watch

The latest on the biggest pipeline moves.

Dermavant’s new topical treatment for plaque psoriasis in adults was approved by the FDA this morning.

The designation is for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI).

Revance Therapeutics announces the FDA has accepted the resubmission for daxibotulinumtoxinA for injection of glabellar lines.

Arcutis Biotherapeutics announced news of its topical roflumilast foam’s trial on safety and efficacy of treatment in scalp and body psoriasis.

Expert panelists discussed the pros, cons, and unknowns of the fast-growing roster of new AD treatments in a session at the 4th Annual Revolutionizing Atopic Dermatitis Conference held April 9 to 11, 2022 in Baltimore, Maryland.

A poster from the 2022 American Academy of Dermatology Annual Meeting presented subgroup analyses from the Effisayil 1 study that showed the efficacy of spesolimab was consistent across all prespecified patient populations, including those with or without IL-36RN mutations.

In this drug pipeline video, Pearl Grimes, MD, FAAD, and Seemal R. Desai, MD, FAAD discuss what's currently happening in the vitiligo pipeline including why current treatments are lacking, what's coming soon, and what it may cost.

In this video interview, Christopher Bunick, MD, PhD dives into the topic of congenital ichthyosis describing his talk on the skin condition at the American Academy of Dermatology 2022 Annual Meeting.

A phase 1 study of davoceticept and pembrolizumab for advanced malignancies received a partial clinical hold from the FDA following a patient death.

Cara Therapeutics announced that difelikefalin—its treatment for moderate to severe pruritus in atopic dermatitis patients—was selected for a late-breaker presentation at the 2022 American Academy of Dermatology annual meeting.